257 related articles for article (PubMed ID: 29264835)
1. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
[TBL] [Abstract][Full Text] [Related]
2. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
4. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
6. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
[TBL] [Abstract][Full Text] [Related]
7. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.
Rodriguez FJ; Scheithauer BW; Giannini C; Bryant SC; Jenkins RB
Cancer; 2008 Nov; 113(10):2779-89. PubMed ID: 18816605
[TBL] [Abstract][Full Text] [Related]
8. Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
Vuong HG; Dunn IF
J Neurooncol; 2022 Aug; 159(1):195-200. PubMed ID: 35768633
[TBL] [Abstract][Full Text] [Related]
9. Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.
Jimenez C; Powers M; Parsa AT; Glastonbury C; Hagenkord JM; Tihan T
J Neurooncol; 2011 Nov; 105(2):317-23. PubMed ID: 21533839
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
11. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
Dardis C; Donner D; Sanai N; Xiu J; Mittal S; Michelhaugh SK; Pandey M; Kesari S; Heimberger AB; Gatalica Z; Korn MW; Sumrall AL; Phuphanich S
BMC Neurol; 2021 Jun; 21(1):231. PubMed ID: 34162346
[TBL] [Abstract][Full Text] [Related]
12. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
14. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H
Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
18. Gliosarcoma. A study of 13 tumors, including p53 and CD34 immunohistochemistry.
Sreenan JJ; Prayson RA
Arch Pathol Lab Med; 1997 Feb; 121(2):129-33. PubMed ID: 9126039
[TBL] [Abstract][Full Text] [Related]
19. The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Zhang Y; Ma JP; Weng JC; Wang L; Wu Z; Li D; Zhang JT
Neurosurg Rev; 2021 Apr; 44(2):1003-1015. PubMed ID: 32189095
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Yu Z; Zhou Z; Xu M; Song K; Shen J; Zhu W; Wei L; Xu H
Comput Math Methods Med; 2023; 2023():1553408. PubMed ID: 36756387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
